^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    KAT6 inhibitor

    Related drugs:
    11d
    Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors. (PubMed, Bioorg Chem)
    PF-07248144 has shown antitumor activity in estrogen receptor-positive (ER+) breast cancer models and is currently undergoing clinical evaluation...This review provides a comprehensive overview of the structural and biological functions of KAT6A, its role in tumor progression, and the therapeutic potential of its inhibition. It summarizes the advancements in KAT6A inhibitor development from 2019 to the present, emphasizing the optimization processes from lead compounds to clinical candidates.
    Review • Journal
    |
    ER (Estrogen receptor) • KAT6A (Lysine Acetyltransferase 6A)
    |
    ER positive
    |
    prifetrastat (PF-07248144)
    17d
    A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine) (clinicaltrials.gov)
    P1, N=12, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • prifetrastat (PF-07248144)
    25d
    A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Stemline Therapeutics, Inc. | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial primary completion date • First-in-human
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    Orserdu (elacestrant) • MEN2312
    25d
    EPIBREAST: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, UNICANCER
    New P2 trial • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 mutation • HER-2 negative + ER positive
    |
    fulvestrant • triptorelin • prifetrastat (PF-07248144)
    26d
    A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine) (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Pfizer
    New P1 trial
    |
    itraconazole • prifetrastat (PF-07248144)
    4ms
    A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 (clinicaltrials.gov)
    P1, N=12, Recruiting, Pfizer
    New P1 trial
    |
    prifetrastat (PF-07248144)
    4ms
    A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Stemline Therapeutics, Inc. | N=124 --> 240
    Enrollment change • First-in-human
    |
    Orserdu (elacestrant) • MEN2312
    5ms
    Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=160, Recruiting, Olema Pharmaceuticals, Inc. | N=90 --> 160
    Enrollment change • First-in-human
    |
    fulvestrant
    6ms
    C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=320, Recruiting, Pfizer | Trial completion date: Jan 2028 --> Sep 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • vepdegestrant (ARV-471) • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    6ms
    A Study of KC1086 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P1 trial
    6ms
    A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, Pfizer
    New P1 trial
    |
    prifetrastat (PF-07248144)
    6ms
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (clinicaltrials.gov)
    P3, N=400, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2027 --> Jul 2027
    Enrollment open • Trial primary completion date
    |
    everolimus • fulvestrant • exemestane • prifetrastat (PF-07248144)